Martek Announces New Infant Formula Licensee

Martek Announces New Infant Formula Licensee Company announces that South Korean infant formula market leader, Namyang Dairy Products Co., Ltd., has signed a license and supply agreement for rights to use Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in South Korea.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EuroPharma Now Offering Products Utilizing New Patented Coating Technology For Specific Uses Company is partnering with a European company to bring a new proprietary and patented enteric coating technology, which preserves active ingredients, to US companies for tablet applications. EcoNugenics® Granted New U.S. Patent for Modified Pectin and Alginates United States Patent and Trademark Office (USPTO) has issued the company US Patent No. 7,026,302. EcoNugenics® Granted New U.S. Patent for Modified Pectin and Alginates United States Patent and Trademark Office (USPTO) has issued the company US Patent No. 7,026,302. EcoNugenics® Granted New U.S. Patent for Modified Pectin and Alginates United States Patent and Trademark Office (USPTO) has issued the company US Patent No. 7,026,302. Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM). Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM). Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM). Collagen Nutraceuticals files for Worldwide Patent Protection on HA Extraction Process and Biofermentation Source announces the filing of worldwide patent protection for their rooster and hen’s comb HA extraction process and biofermentation method, utlizied in manufacturing PureHA(TM). Patent Issued for SLIMALUMA Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same." Patent Issued for SLIMALUMA Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same." Patent Issued for SLIMALUMA Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same." Patent Issued for SLIMALUMA Company has been awarded US Patent No. 7,060,308 for "Caralluma Extract Products and Processes for Making the same." Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control. Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control. Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control. Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control. Global Pharmatech Announces a Patent Granted on Its Jutai Soft Capsule Product Company announces it has been granted an invention patent (ZL03119221.1) on its Jutai soft capsules product containing American Ginseng and Echinacea, with patent protection over the methods of product preparation, utility as well as methods of quality control. NutraCea Continues to Expand Its International Patent Portfolio Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655. NutraCea Continues to Expand Its International Patent Portfolio Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655. NutraCea Continues to Expand Its International Patent Portfolio Company announces today that its Mexican Patent Application entitled "Supportive Therapy for Diabetes, Hyperglycemia and Hypoglycemia" has been allowed by the Mexican Industrial Property Office with patent number 232655. Austrian Court Upholds Novogen Patent for Red Clover Isoflavones Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld. Austrian Court Upholds Novogen Patent for Red Clover Isoflavones Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld. Austrian Court Upholds Novogen Patent for Red Clover Isoflavones Vienna Commercial Court has found that Novogen's (NVGN) isoflavone invention and patent is novel and inventive, and found APOtrend's menopause product Vitalady infringed Novogen's patent and the provisional injunction against Vitalady has been upheld. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Nutrition Formulators, Inc. Completes Its First Generation of Fast Dissolving Supplements Company has developed an innovative line of fast dissolving tablets for dietary supplements. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Bayer Pharma Signs Agreement with Vitiva Bayer Pharma, Slovenia and Vitiva, Slovenia announced today a new broad technology collaboration, based on exclusive isolation of esters from marigold flower, with Bayer Pharma has registering a patent for a natural OTC product worldwide based on marigold flower extracts. Notice of Request for Proposals for Stevia rebaudiana Cultivars Agriculture and Agri-Food Canada is offering an RFP for the licensed right to produce and market Stevia rebaudiana cultivars, seed and/or product. Notice of Request for Proposals for Stevia rebaudiana Cultivars Agriculture and Agri-Food Canada is offering an RFP for the licensed right to produce and market Stevia rebaudiana cultivars, seed and/or product. Notice of Request for Proposals for Stevia rebaudiana Cultivars Agriculture and Agri-Food Canada is offering an RFP for the licensed right to produce and market Stevia rebaudiana cultivars, seed and/or product. Notice of Request for Proposals for Stevia rebaudiana Cultivars Agriculture and Agri-Food Canada is offering an RFP for the licensed right to produce and market Stevia rebaudiana cultivars, seed and/or product. New Patent Promotes Soy Isoflavone Benefits The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls. New Patent Promotes Soy Isoflavone Benefits The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls. New Patent Promotes Soy Isoflavone Benefits The U.S. Patent Office has issued patent number 7,045,155 to Novogen, Ltd; This patent, which Acatris has exclusively licensed, protects compositions for the amelioration of human health conditions that are responsive to treatment with phyto-estrogens. The compositions comprise phytoestrogen-enriched extracts primarily from soy hypocotyls. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. ReGen Signs First Commercialisation Deal for Colostrinin(TM) with Metagenics Company has entered into an exclusive licence agreement with Metagenics, Inc. for the commercialisation of ReGen's Colostrinin(TM) as a human nutraceutical in North America. NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity Company announces a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease Fuji Chemical Granted Inflammation Patent For Astaxanthin Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin. Fuji Chemical Granted Inflammation Patent For Astaxanthin Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin. Fuji Chemical Granted Inflammation Patent For Astaxanthin Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxnathin. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Provexis Announces Exclusivity Agreement Company has entered into an exclusivity agreement for a period of 12 months with a major global branded food business for the joint development and use of its patented Fruitflow(TM) heart-health technology. Carotech Enters into Exclusive Arrangement with Metagenics for Tocomin® SupraBio(TM) for the Healthcare Practitioner Market Company has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin® SupraBio(TM) – a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel of distribution in North America. Carotech Enters into Exclusive Arrangement with Metagenics for Tocomin® SupraBio(TM) for the Healthcare Practitioner Market Company has entered into an exclusive license agreement with Metagenics, Inc. for the commercialization of Tocomin® SupraBio(TM) – a patented, bio-enhanced, natural, full-spectrum palm tocotrienol complex for the healthcare practitioner channel of distribution in North America. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	COLUMBIA, Md., June 28, 2006 /PRNewswire-FirstCall via COMTEX/ -- Martek Biosciences Corporation (MATK) announced today that South Korean infant formula market leader, Namyang Dairy Products Co., Ltd., has signed a license and supply agreement for rights to use Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in South Korea. Martek manufactures nutritional oils that contain the long-chain polyunsaturated fatty acids, DHA and ARA, both of which are naturally present in breast milk. Clinical studies have demonstrated benefits for those infants receiving DHA and ARA supplemented formula. Martek's proprietary blend of DHA and ARA is the first source of these nutrients cleared for use in U.S. infant formula by the FDA and is the only source being used in the U.S. by infant formula manufacturers. Martek's DHA and ARA are currently being sold by the Company's licensees in supplemented formulas in over 65 countries around the world. "This agreement is yet another example of how formula manufacturers worldwide are recognizing the benefits of adding DHA and ARA to formula, both for their business and the infants they serve. I always feel great that, with every new license agreement, more and more infants around the world will benefit from Martek's products," said Henry "Pete" Linsert, Jr., chairman and CEO of Martek Biosciences Corporation. Martek Biosciences Corporation (MATK) is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces Martek DHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula, and supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com. Sections of this release contain forward-looking statements concerning, among other things, expectations regarding inclusion of Martek's products in infant formulas in the US and elsewhere. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, Part II, Item 1A of the Company's Form 10-Q for the fiscal quarter ended April 30, 2006 and other filed reports on Form 10-K/A, Form 10-Q and Form 8-K. CONTACT: Cassie France-Kelly, Public Relations, +1-443-542-2116, cfrancekelly@martekbio.com, or Kyle Stults, Investor Relations, +1-410-740-0081, kstults@martekbio.com, both of Martek Biosciences Corporation.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software